AXSM enters the back half of June with an unusual tension: a fresh analyst upgrade pushing the price target ceiling higher while short sellers quietly rebuild positions at the fastest pace in months.
TD Cowen's Joseph Thome raised his target from $275 to $300 this week — today's action, within the last 24 hours — keeping a Buy rating on the stock. That move sits at the optimistic end of a Street that has been broadly constructive since the Q1 print in early May, when a wave of houses lifted targets simultaneously: RBC to $302, Mizuho to $310, Wells Fargo to $255, Guggenheim to $260. The mean price target across the group now runs at $276, against a current price of $251.91, implying roughly 10% upside to consensus. Morgan Stanley remains the outlier, holding an Equal-Weight with a $242 target — the lone voice keeping a lid on enthusiasm. The bull case rests on two commercialised drugs and a pipeline with several late-stage assets, backed by a cash position management says extends to profitability. The bear case is more mechanical: payer coverage friction for Auvelity and Sunosi, a crowded CNS competitive landscape, and a salesforce expansion that lifts expenses before it lifts revenue.
Short positioning tells a more complicated story than the analyst consensus implies. Short interest climbed 11.5% in the past week and 13% over the past month, reaching 6.1% of the free float — a level worth watching in a mid-cap specialty pharma name. The move came in a step-change: borrowing sat around 2.75 million shares through late May, then jumped to roughly 3.1 million during the week of June 9, where it has held. Despite that build, the lending market is not tight by any measure. Availability is extraordinarily loose at nearly 6,000% — meaning there are roughly 30 million shares available to borrow against the 3 million currently shorted — and cost to borrow has stayed below 0.5% throughout, essentially free money to maintain a position. The short score of 44.5 is consistent with this: moderate, not extreme, well below levels that typically flag crowded positioning.
Options positioning has actually become slightly less defensive than usual. The put/call ratio ticked down to 0.95 this week, a full standard deviation below its 20-day average of 0.99. That's a quiet but notable contrast to the short interest build — call buyers have been marginally more active than put buyers, and the ratio is well off its 52-week high of 1.06. The next earnings event is pencilled in for August 3, giving that divergence time to develop further.
The insider activity from the past week deserves attention. CEO Herriot Tabuteau sold 49,670 shares on June 9 for just under $12 million, while CFO Nick Pizzie sold 33,000 shares for roughly $7.9 million on the same day. Several independent directors also sold smaller tranches across June 9 and 10. The 90-day net insider position is positive in share terms — 114,272 net shares — but the dollar value of $26.8 million net over that window is heavily shaped by prior activity rather than recent buying. These June sales follow stock awards in the same week, which is a common pattern, though the scale of the CEO and CFO exits is notable at a stock trading near all-time highs.
Factor scores add a final layer of context. EPS momentum ranks in the 97th and 98th percentile over 30 and 90 days respectively — extraordinary by any standard — and the EPS surprise rank sits at the 86th percentile. Valuation multiples reflect the premium: a PE of 142x has compressed 56 points over the past month as earnings estimates have moved up faster than the stock. EV/EBITDA at 269x tells a similar story — expensive on traditional metrics, but with the earnings acceleration embedded in the momentum scores, the Street appears willing to pay for the trajectory rather than the current level.
What to watch heading into August: whether the short interest build continues to accelerate or plateaus near 6% of float, and whether the CEO and CFO sale volumes represent routine liquidity events or a shift in insider conviction at current prices.
See the live data behind this article on ORTEX.
Open AXSM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
